tradingkey.logo
tradingkey.logo
Search

Indivior PLC

INDV
Add to Watchlist
39.500USD
-0.100-0.25%
Close 05/08, 16:00ETQuotes delayed by 15 min
4.78BMarket Cap
23.51P/E TTM

Indivior PLC

39.500
-0.100-0.25%
View Detailed Chart
Intraday
1m
30m
1h
D
W
M
D

Today

-0.25%

5 Days

+4.89%

1 Month

+23.67%

6 Months

+26.04%

Year to Date

+10.09%

1 Year

+259.74%

TradingKey Stock Score of Indivior PLC

Currency: USD Updated: 2026-05-08

Key Insights

Indivior PLC's fundamentals are relatively healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 11 out of 156 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 49.83.In the medium term, the stock price is expected to trend up.The company has been performing strongly in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Indivior PLC's Score

Industry at a Glance

Industry Ranking
11 / 156
Overall Ranking
49 / 4494
Industry
Pharmaceuticals

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score
Previous score

Media Coverage

Last 24 hours
Coverage Level

Very Low
Very High
Neutral

Indivior PLC Highlights

StrengthsRisks
Indivior PLC is a global pharmaceutical company engaged in developing medicines to treat substance-use disorders (SUD). The Company provides treatment for addiction, including SUBLOCADE (buprenorphine extended-release) injection for subcutaneous use, a long-acting injectable (LAI) for opioid use disorder and OPVEE (Nalmefene) nasal spray for opioid overdose recovery. Its core products include SUBOXONE Film, SUBOXONE Tablet, SUBUTEX Tablet, OPVEE (nalmefene), and SUBLOCADE. SUBOXONE Film is a buprenorphine and naloxone sublingual film. SUBOXONE Tablet is a buprenorphine and naloxone sublingual tablet. SUBUTEX Tablet is a buprenorphine sublingual tablet. SUBOXONE Film, SUBOXONE Tablet, SUBUTEX Tablet, and SUBLOCADE are treatments for opioid use disorder (OUD). In addition to its commercially available products, its product pipeline includes two drug candidates for the treatment of OUD. The Company sells its products in the United States and in other selected areas of the world.
Fairly Valued
The company’s latest PE is 23.51, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 121.22M shares, decreasing 8.77% quarter-over-quarter.
Held by PRFDX
Star Investor PRFDX holds 32.33K shares of this stock.

Analyst Rating

Based on 6 analysts
Buy
Current Rating
49.833
Target Price
+27.84%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Indivior PLC News

More news coming soon, stay tuned...

Financial Indicators

EPS

Relevant data have not been disclosed by the company yet.

Total revenue

Relevant data have not been disclosed by the company yet.

Indivior PLC Info

Indivior PLC is a global pharmaceutical company engaged in developing medicines to treat substance-use disorders (SUD). The Company provides treatment for addiction, including SUBLOCADE (buprenorphine extended-release) injection for subcutaneous use, a long-acting injectable (LAI) for opioid use disorder and OPVEE (Nalmefene) nasal spray for opioid overdose recovery. Its core products include SUBOXONE Film, SUBOXONE Tablet, SUBUTEX Tablet, OPVEE (nalmefene), and SUBLOCADE. SUBOXONE Film is a buprenorphine and naloxone sublingual film. SUBOXONE Tablet is a buprenorphine and naloxone sublingual tablet. SUBUTEX Tablet is a buprenorphine sublingual tablet. SUBOXONE Film, SUBOXONE Tablet, SUBUTEX Tablet, and SUBLOCADE are treatments for opioid use disorder (OUD). In addition to its commercially available products, its product pipeline includes two drug candidates for the treatment of OUD. The Company sells its products in the United States and in other selected areas of the world.
Ticker SymbolINDV
CompanyIndivior PLC
CEOCiaffoni (Joseph J)
Websitehttps://www.indivior.com/en
KeyAI